CN101903340B - 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 - Google Patents
取代的n-苯基联吡咯烷羧酰胺及其治疗用途 Download PDFInfo
- Publication number
- CN101903340B CN101903340B CN2008801212081A CN200880121208A CN101903340B CN 101903340 B CN101903340 B CN 101903340B CN 2008801212081 A CN2008801212081 A CN 2008801212081A CN 200880121208 A CN200880121208 A CN 200880121208A CN 101903340 B CN101903340 B CN 101903340B
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- bipyrrolidine
- carboxylic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(CCC1)N1C(CC1)CN1c(cc1)ccc1N Chemical compound *C(CCC1)N1C(CC1)CN1c(cc1)ccc1N 0.000 description 5
- LFMNOHYCZLVTQR-UHFFFAOYSA-N CC(CCC1)N1C(CC1)CN1c(cc1)c(C)cc1NC(C1CC1)=O Chemical compound CC(CCC1)N1C(CC1)CN1c(cc1)c(C)cc1NC(C1CC1)=O LFMNOHYCZLVTQR-UHFFFAOYSA-N 0.000 description 1
- ZETKRQDDYKMOPO-UHFFFAOYSA-N CC(CCC1)N1C(CC1)CN1c(cc1)ccc1NC(C1C(C)(C)C1(C)C)=O Chemical compound CC(CCC1)N1C(CC1)CN1c(cc1)ccc1NC(C1C(C)(C)C1(C)C)=O ZETKRQDDYKMOPO-UHFFFAOYSA-N 0.000 description 1
- JVRCPBUFCJRHEI-HJWRWDBZSA-N CC(CN(C)C(/C=C\C(NC(C1CC1)=O)=C)=C)N1C(C)CCC1 Chemical compound CC(CN(C)C(/C=C\C(NC(C1CC1)=O)=C)=C)N1C(C)CCC1 JVRCPBUFCJRHEI-HJWRWDBZSA-N 0.000 description 1
- BTNJIWYZQYOUJA-STQMWFEESA-N CCC(C)(C)OC(N(CC1)C[C@H]1N1[C@@H](C)CCC1)=O Chemical compound CCC(C)(C)OC(N(CC1)C[C@H]1N1[C@@H](C)CCC1)=O BTNJIWYZQYOUJA-STQMWFEESA-N 0.000 description 1
- QQFAGVRJPSCEIU-UHFFFAOYSA-N CCC(C)N(C)C(CC1)CN1C(OC(C)(C)C)=O Chemical compound CCC(C)N(C)C(CC1)CN1C(OC(C)(C)C)=O QQFAGVRJPSCEIU-UHFFFAOYSA-N 0.000 description 1
- AVZBGWPCVDJMMY-UHFFFAOYSA-N CCCN(C)C(CC1)CN1c(cc1)ccc1N Chemical compound CCCN(C)C(CC1)CN1c(cc1)ccc1N AVZBGWPCVDJMMY-UHFFFAOYSA-N 0.000 description 1
- WFSAHCWIQYOYHH-WMZOPIPTSA-N C[C@@H](CCC1)N1[C@@H](CC1)CN1c(cc1)cc(C)c1NC(c1ccc[o]1)=O Chemical compound C[C@@H](CCC1)N1[C@@H](CC1)CN1c(cc1)cc(C)c1NC(c1ccc[o]1)=O WFSAHCWIQYOYHH-WMZOPIPTSA-N 0.000 description 1
- RAICQPFLQTZKOQ-HIFRSBDPSA-N C[C@H](CCC1)N1[C@@H](CC1)CN1c(cc1)cc(C)c1N Chemical compound C[C@H](CCC1)N1[C@@H](CC1)CN1c(cc1)cc(C)c1N RAICQPFLQTZKOQ-HIFRSBDPSA-N 0.000 description 1
- CFNGUJUWGIXAEI-UHFFFAOYSA-N Cc(cc(cc1)NC(C2CCOCC2)=O)c1N(CC1)CC1N(CCC1)C1N Chemical compound Cc(cc(cc1)NC(C2CCOCC2)=O)c1N(CC1)CC1N(CCC1)C1N CFNGUJUWGIXAEI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98059907P | 2007-10-17 | 2007-10-17 | |
| US60/980,599 | 2007-10-17 | ||
| PCT/US2008/079757 WO2009052062A1 (en) | 2007-10-17 | 2008-10-14 | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101903340A CN101903340A (zh) | 2010-12-01 |
| CN101903340B true CN101903340B (zh) | 2013-03-27 |
Family
ID=40247942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801212081A Expired - Fee Related CN101903340B (zh) | 2007-10-17 | 2008-10-14 | 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8088808B2 (enExample) |
| EP (1) | EP2212283B1 (enExample) |
| JP (1) | JP5377503B2 (enExample) |
| KR (1) | KR20100072077A (enExample) |
| CN (1) | CN101903340B (enExample) |
| AT (1) | ATE525351T1 (enExample) |
| AU (1) | AU2008312635B2 (enExample) |
| BR (1) | BRPI0818581A2 (enExample) |
| CA (1) | CA2702467C (enExample) |
| CY (1) | CY1112083T1 (enExample) |
| DK (1) | DK2212283T3 (enExample) |
| ES (1) | ES2372332T3 (enExample) |
| HR (1) | HRP20110762T1 (enExample) |
| IL (1) | IL205001A (enExample) |
| MA (1) | MA31858B1 (enExample) |
| MX (1) | MX2010003949A (enExample) |
| MY (1) | MY151348A (enExample) |
| NZ (1) | NZ584690A (enExample) |
| PL (1) | PL2212283T3 (enExample) |
| PT (1) | PT2212283E (enExample) |
| RS (1) | RS52235B (enExample) |
| RU (1) | RU2477720C2 (enExample) |
| SI (1) | SI2212283T1 (enExample) |
| WO (1) | WO2009052062A1 (enExample) |
| ZA (1) | ZA201002115B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ584692A (en) | 2007-10-17 | 2011-12-22 | Sanofi Aventis | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
| ES2392122T3 (es) | 2007-10-17 | 2012-12-04 | Sanofi | N-fenil-pirrolidinilmetilpirrolidin amidas sustituidas y uso terapéutico de las mismas |
| PL2212283T3 (pl) * | 2007-10-17 | 2012-01-31 | Sanofi Sa | Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne |
| WO2009052065A1 (en) | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| AR074467A1 (es) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| WO2011143163A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| TW201206444A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| EP2569294B1 (en) | 2010-05-11 | 2015-03-11 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| TW201206910A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
| TW201206889A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| AR083718A1 (es) | 2010-05-11 | 2013-03-20 | Sanofi Aventis | Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas |
| WO2011143148A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| SG186275A1 (en) | 2010-07-06 | 2013-01-30 | Astrazeneca Ab | Therapeutic agents 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| JP2013232564A (ja) * | 2012-04-27 | 2013-11-14 | National Institute Of Advanced Industrial & Technology | 半導体装置および半導体装置の製造方法 |
| CN108250128A (zh) * | 2012-09-27 | 2018-07-06 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
| MX2015008919A (es) | 2013-01-10 | 2015-10-22 | Gruenenthal Gmbh | Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac). |
| JP2016504397A (ja) | 2013-01-10 | 2016-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉｉ |
| EP3366683A1 (en) | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| JP2006505590A (ja) * | 2002-10-23 | 2006-02-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0608523A2 (pt) | 2005-03-17 | 2010-11-16 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir receptor de histamina h3 em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, para tratar ou prevenir obesidade e para tratar ou prevenir um distúrbio ou doença, e, uso de um composto ou um sal do mesmo |
| WO2006107661A1 (en) * | 2005-04-01 | 2006-10-12 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| MX2007016216A (es) * | 2005-07-01 | 2008-03-11 | Lilly Co Eli | Agenes del receptor de histamina h3, preparacion y usos terapeuticos. |
| US7943605B2 (en) * | 2005-10-27 | 2011-05-17 | Ucb Pharma S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| WO2007093364A1 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| WO2009052065A1 (en) * | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| NZ584692A (en) * | 2007-10-17 | 2011-12-22 | Sanofi Aventis | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
| ES2392122T3 (es) | 2007-10-17 | 2012-12-04 | Sanofi | N-fenil-pirrolidinilmetilpirrolidin amidas sustituidas y uso terapéutico de las mismas |
| PL2212283T3 (pl) * | 2007-10-17 | 2012-01-31 | Sanofi Sa | Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne |
-
2008
- 2008-10-14 PL PL08839959T patent/PL2212283T3/pl unknown
- 2008-10-14 CA CA2702467A patent/CA2702467C/en not_active Expired - Fee Related
- 2008-10-14 CN CN2008801212081A patent/CN101903340B/zh not_active Expired - Fee Related
- 2008-10-14 ES ES08839959T patent/ES2372332T3/es active Active
- 2008-10-14 SI SI200830416T patent/SI2212283T1/sl unknown
- 2008-10-14 AT AT08839959T patent/ATE525351T1/de active
- 2008-10-14 MY MYPI20101299 patent/MY151348A/en unknown
- 2008-10-14 KR KR1020107010769A patent/KR20100072077A/ko not_active Ceased
- 2008-10-14 NZ NZ584690A patent/NZ584690A/en not_active IP Right Cessation
- 2008-10-14 AU AU2008312635A patent/AU2008312635B2/en not_active Ceased
- 2008-10-14 BR BRPI0818581-6A patent/BRPI0818581A2/pt not_active IP Right Cessation
- 2008-10-14 DK DK08839959.7T patent/DK2212283T3/da active
- 2008-10-14 EP EP08839959A patent/EP2212283B1/en active Active
- 2008-10-14 JP JP2010530049A patent/JP5377503B2/ja not_active Expired - Fee Related
- 2008-10-14 PT PT08839959T patent/PT2212283E/pt unknown
- 2008-10-14 RU RU2010119528/04A patent/RU2477720C2/ru not_active IP Right Cessation
- 2008-10-14 WO PCT/US2008/079757 patent/WO2009052062A1/en not_active Ceased
- 2008-10-14 MX MX2010003949A patent/MX2010003949A/es active IP Right Grant
- 2008-10-14 RS RS20110522A patent/RS52235B/sr unknown
- 2008-10-14 HR HR20110762T patent/HRP20110762T1/hr unknown
-
2010
- 2010-03-15 US US12/724,028 patent/US8088808B2/en not_active Expired - Fee Related
- 2010-03-25 ZA ZA2010/02115A patent/ZA201002115B/en unknown
- 2010-04-11 IL IL205001A patent/IL205001A/en not_active IP Right Cessation
- 2010-05-17 MA MA32850A patent/MA31858B1/fr unknown
-
2011
- 2011-11-18 US US13/299,574 patent/US8252824B2/en not_active Expired - Fee Related
- 2011-11-24 CY CY20111101151T patent/CY1112083T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101903340B (zh) | 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 | |
| CN101903341B (zh) | 取代的n-苯基-联吡咯烷脲及其治疗用途 | |
| CN101903339B (zh) | 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途 | |
| CN101903342B (zh) | 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途 | |
| CN102239170B (zh) | 取代的四氢吡喃螺吡咯烷酮和哌啶酮及其制备和治疗用途 | |
| HK1146053B (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| HK1146056B (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| HK1146054B (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| HK1146055B (en) | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1146053 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1146053 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130327 Termination date: 20171014 |